Chronic Inflammatory Muscle Diseases and Risk of Coronary Artery Disease

Coronary Heart Disease (JA Farmer, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Coronary Heart Disease

Abstract

Despite recent advancements in the treatment of coronary artery disease (CAD), it remains the commonest cause of death in the world. Although traditional risk factors partially account for the development of CAD, other novel risk factors have recently been implicated. Specifically, chronic inflammation has been postulated to play a role in the development and propagation of this disease. The purpose of this review is to examine the available evidence to determine if patients with chronic inflammatory muscle diseases have higher rates of cardiovascular disease.

Keywords

Chronic inflammatory muscle diseases Coronary artery disease Endothelial dysfunction 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Eyre H, Kahn R, Robertson RM. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. CA Cancer J Clin. 2004;54:190–207.PubMedCrossRefGoogle Scholar
  2. 2.
    Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.PubMedCrossRefGoogle Scholar
  3. 3.
    Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTER- HEART study): case-control study. Lancet. 2004;364:937–52.PubMedCrossRefGoogle Scholar
  4. 4.
    •• Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83:456S–60S. This article is of major importance because it reviews the mechanism of inflammatory mediators in CAD.PubMedGoogle Scholar
  5. 5.
    • Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med. 2008;121:S21–31. This article is of importance because it evaluates the potential role of chronic inflammatory diseases in the cause of CAD.PubMedCrossRefGoogle Scholar
  6. 6.
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRefGoogle Scholar
  7. 7.
    Trion A, de Maat MP, Jukema JW, et al. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol. 2005;25:1635–40.PubMedCrossRefGoogle Scholar
  8. 8.
    Tennent GA, Hutchinson WL, Kahan MC, et al. Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. Atherosclerosis. 2008;196:248–55.PubMedCrossRefGoogle Scholar
  9. 9.
    Ortiz MA, Campana GL, Woods JR, et al. Continuously-infused human C-reactive protein is neither proatherosclerotic nor proinflammatory in apolipoprotein E-deficient mice. Exp Biol Med (Maywood). 2009;234:624–31.CrossRefGoogle Scholar
  10. 10.
    Torzewski M, Reifenberg K, Cheng F, et al. No effect of C-reactive protein on early atherosclerosis in LDLR-/- human C-reactive protein transgenic mice. Thromb Haemost. 2008;99:196–201.PubMedGoogle Scholar
  11. 11.
    Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897–908.PubMedCrossRefGoogle Scholar
  12. 12.
    Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein, genetically elevated levels and risk of ischemic heart and cerebrovascular disease. Scand J Clin Lab Invest. 2009;69:442–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Dalakas MC. Inflammatory muscle diseases; a critical review on pathogenesis and therapies. Curr Opin Pharmacol. 2010;10:346–52.PubMedCrossRefGoogle Scholar
  14. 14.
    Schmidt J, Dalakas MC. Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. Exp Opin. 2010;4:241–50.Google Scholar
  15. 15.
    Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med. 1991;325:1487–98.PubMedCrossRefGoogle Scholar
  16. 16.
    Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–82.PubMedCrossRefGoogle Scholar
  17. 17.
    Engel AG, Hohlfeld R, Banker BQ. The polymyositis and dermatomyositis syndrome. In: Engel AG, editor. Myology. New York: McGraw-Hill; 2008. p. 1335–83.Google Scholar
  18. 18.
    •• Tisseverasinghe A, Bernatsky S, Pineau CA. Arterial events in persons with dermatomyositis and polymyositis. J Rheumatol. 2009;36:1943–6. This article is of major importance because it defines a possible association between chronic inflammatory muscle diseases and CAD.PubMedCrossRefGoogle Scholar
  19. 19.
    Szmitko PE, Wang CH, Weisel RD, et al. New markers of inflammation and endothelial cell activation: part I. Circulation. 2003;108:1917–23.PubMedCrossRefGoogle Scholar
  20. 20.
    Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002;105:546–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003;108:2054–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Verma S, Szmitko PE, Anderson TJ. Endothelial function: ready for prime time? Can J Cardiol. 2004;20:1335–9.PubMedGoogle Scholar
  23. 23.
    Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839–44.PubMedCrossRefGoogle Scholar
  24. 24.
    Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol. 2008;101:23F–33F.PubMedCrossRefGoogle Scholar
  25. 25.
    Liuzzo G. Atherosclerosis: an inflammatory disease. Rays. 2001;26:221–30.PubMedGoogle Scholar
  26. 26.
    Heeschen C, Dimmeler S, Hamm CW, et al. Serum level of the anti inflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation. 2003;107:2109–14.PubMedCrossRefGoogle Scholar
  27. 27.
    Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus Panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106:388–91.PubMedCrossRefGoogle Scholar
  28. 28.
    Zebrack JS, Anderson JL, Maycock CA, et al. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol. 2002;89:145–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Zebrack JS, Muhlestein JB, Horne BD, Anderson JL. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol. 2002;39:632–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 Anti-Platelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol. 2000;35:1535–42.PubMedCrossRefGoogle Scholar
  31. 31.
    Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417–24.PubMedCrossRefGoogle Scholar
  32. 32.
    Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. Circulation. 1997;96:4204–10.PubMedCrossRefGoogle Scholar
  33. 33.
    Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta- analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:483–95.PubMedGoogle Scholar
  34. 34.
    Dalakas MC. Adaptive immunity and atherosclerosis. Pathophysiology of inflammatory and autoimmune myopathies. Presse Med. 2011;40(4 Pt 2):e237–47.PubMedCrossRefGoogle Scholar
  35. 35.
    Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol. 2010;134(1):33–46.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of Arkansas for Medical SciencesLittle RockUSA

Personalised recommendations